No Needles? The New FDA Approved GLP-1 Pill Could Change Obesity Treatment for Black Women...

Published: July 30th 2026

By Just Listen to Us (JL2US)

A New Chapter in Weight Management

For years, medications like Ozempic®, Wegovy®, and Zepbound® have transformed the conversation around obesity treatment. While these injectable GLP-1 medications have helped many people achieve significant weight loss and improve blood sugar control, injections are not the right choice—or the preferred choice—for everyone, including for some Black women.

Now, the U.S. Food and Drug Administration (FDA) has approved Foundayo® (orforglipron), a once-daily oral GLP-1 medication for adults living with obesity or overweight with at least one weight-related health condition. Unlike injectable GLP-1 medications, Foundayo is taken as a pill and does not require fasting or special timing with food or water, offering patients a potentially more convenient treatment option.

The approval represents another milestone in the rapidly evolving field of obesity medicine and may offer a new alternative for those who have been reluctant or unable to use injectable therapies.

What Is a GLP-1 Medication?

GLP-1 (glucagon-like peptide-1) receptor agonists work by mimicking a naturally occurring hormone (incretin) that helps regulate appetite, slows stomach emptying, and signals the brain when the body feels full. For many patients, these medications can reduce hunger, decrease food intake, improve blood sugar control, and support meaningful weight loss when combined with healthy eating and regular physical activity.

Clinical trials found that participants taking Foundayo experienced clinically meaningful weight loss over 72 weeks compared with those receiving a placebo. Like other GLP-1 medications, common side effects included nausea, constipation, diarrhea, vomiting, and abdominal discomfort. The medication also carries important warnings, including a boxed warning regarding the risk of thyroid C-cell tumors in certain patients.

Why This Matters for Black Women

This approval is especially relevant for Black women because obesity and type 2 diabetes continue to disproportionately affect our demographic.

According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), 56.9% of non-Hispanic Black women have obesity, the highest prevalence among all major racial and ethnic groups in the United States. The U.S. Department of Health and Human Services also reports that about 4 in 5 Black women have overweight or obesity.

The impact extends beyond weight alone.

Black Americans also experience higher rates of diagnosed type 2 diabetes than many other racial and ethnic groups, increasing the risk of heart disease, stroke, kidney disease, vision loss, and other serious complications.

These disparities are influenced by far more than personal choices. Researchers point to a complex combination of factors, including limited access to healthy foods, fewer safe spaces for physical activity, chronic stress, structural inequities, healthcare access, neighborhood environments, and other social determinants of health. Understanding these broader influences is essential when discussing obesity and diabetes in Black communities.

Beyond Weight Loss

Although GLP-1 medications have gained attention for helping people lose weight, researchers are increasingly recognizing that their benefits may extend well beyond the number on a scale.

Weight loss can improve blood sugar control, reduce blood pressure, decrease the risk of cardiovascular disease, lessen stress on joints, improve sleep apnea, and enhance overall quality of life. For some women, weight loss may also improve symptoms associated with polycystic ovary syndrome (PCOS) and support fertility goals, although treatment decisions should always be made in consultation with a healthcare provider.

The approval of an oral GLP-1 medication may also make treatment feel more accessible for individuals who are uncomfortable with injections or prefer the convenience of taking a daily pill.

Why JL2US Is Following This Story

At Just Listen to Us (JL2US), we believe innovations in medicine should be viewed through the lens of health equity.

Black women continue to experience disproportionately high rates of obesity, diabetes, cardiovascular disease, and other chronic conditions that can significantly affect quality of life. Breakthroughs like Foundayo represent more than a new medication—they expand the conversation about prevention, treatment, and the importance of offering patients choices that fit their lives and preferences.

While no medication is a substitute for comprehensive healthcare, healthy nutrition, physical activity, and supportive communities, advances like this have the potential to become one important tool in addressing chronic diseases that have disproportionately impacted Black women for generations.

JL2US will continue following emerging research, FDA approvals, and medical innovations that empower Black women with trusted, evidence-based information to make informed healthcare decisions.

References & Further Reading

Official Sources

- "FDA: Foundayo (orforglipron) Approval Announcement" (https://reference-url-citation.invalid/6)

- "DailyMed: Foundayo Prescribing Information" (https://reference-url-citation.invalid/7)

Obesity & Diabetes Statistics

- "National Institute of Diabetes and Digestive and Kidney Diseases: Overweight & Obesity Statistics" (https://reference-url-citation.invalid/8)

- "Office on Women's Health: Weight and Obesity" (https://reference-url-citation.invalid/9)

- "CDC: National Diabetes Statistics Report" (https://reference-url-citation.invalid/10)

Additional Reading

- "Medical News Today: FDA Approves Foundayo Oral GLP-1 Pill" (https://reference-url-citation.invalid/11)

- "Associated Press: FDA Approves Eli Lilly's Weight-Loss Pill" (https://reference-url-citation.invalid/12)